Bravecto is available as a spot-on flea and tick treatment for cats – providing 3 months protection.
Why choose Bravecto spot-on for your cat:
Bravecto contains fluralaner.
Bravecto spot-on should be administered in accordance with the following (corresponding to a dose of 40 – 94 mg fluralaner/kg body weight):
Bodyweight (kg) of cat
Small (1.2 – 2.8kgs) 0.4 mL/pipette
Medium (> 2.8 – 6.25kgs) 0.89 mL/pipette
Large (> 6.25 – 12.5kgs) 1.79 mL/pipette
*For use in cats from 9 weeks of age and over 1.2kg.
For optimal control of tick and flea infestation, the Bravecto spot-on should be administered at 3 monthly intervals. Bravecto spot-on can be administered all year round. Apply spot-on to the skin at the base of the cat's head, to ensure the solution cannot be licked off. Apply in 1 spot for cats 1.2kg – 6.25kg, and 2 spots for cats over 6.25kg.
1 x single dose packs
No adverse reactions were observed following topical administration to kittens aged 9-13 weeks and weighing 1.2-1.5 kg treated with overdoses of up to 5 times the maximum recommended dose (93 mg, 279 mg and 465 mg fluralaner/kg body weight) on three occasions at shorter intervals than recommended (8-week intervals).
Less than 2.5% of treated cats in clinical trials developed mild and transient skin reactions at the application site such as erythema (reddened skin) and itching or hair loss. Uncommonly, the following other signs shortly after application were observed: apathy (lethargy)/tremors/anorexia (lack of appetite) or vomiting/hypersalivation (drooling). If licking of the application site occurs, transient mild to moderate salivation and coughing or vomiting may be observed.
Fluralaner is part of the isoxazoline family of chemicals. Adverse reactions to this family of chemicals are rarely observed but may include vomiting, diarrhoea, lethargy, inappetence, itching and very rarely neurological signs including tremors, ataxia and seizures. Most adverse reactions are self-limiting and of short duration. If you have any concerns, please speak to your veterinarian.
If hypersensitivity to the active substance or to any of the excipients is known or suspected, do not use this product.
The safety has not been established in kittens less than 9 weeks old and/or cats weighing less than 1.2 kg. The safety has not been established for treatment with this product when administered at intervals shorter than 8 weeks. The safety of the product has not been established during pregnancy and lactation.